The race for a vaccine


As soon as Pfizer and its partner BioNTech announced that their Covid-19 vaccine has 95% efficacy, stock markets across the globe went berserk to price in an economic recovery. The damage on rubber glove counters was real, with a free fall in their share prices since last week, before bargain hunters came in to bottom fish yesterday.

IT WAS perhaps the only single piece of news that investors around the world wanted to hear. As soon as Pfizer and its partner BioNTech announced that their Covid-19 vaccine has 95% efficacy, stock markets across the globe went berserk to price in an economic recovery.

The damage on rubber glove counters was real, with a free fall in their share prices since last week, before bargain hunters came in to bottom fish yesterday.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Wall St set for higher open as prospects of September rate cut grow
Eupe Corp estimates bangsar project to generate RM300mil GDV
UEM Sunrise remains optimistic with RM2.7bil unbilled sales
Collaboration with Tesla expected to drive Malaysia to be main green technology hub in region - Tengku Zafrul
Mega First's net profit increases to RM105.35mil in 2Q
TSH Resources eyes expansion into renewable energy
SunCon upbeat on FY24 growth, boosted by RM7.4bil order book
Ringgit ends slightly lower vs greenback ahead of Fed chairman speech
Kossan remains positive on long-term glove demand
Capital A unit to issue revenue bonds worth up to US$443mil

Others Also Read